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a b s t r a c t 
Chemokines act mainly in guiding leukocyte migration along the endothelium. Apart from angiogenesis or
neuronal survival, chemokines are involved in damage and repair of brain tissue after ischemic stroke. We
studied the presence of chemokines directly in neurons and brain blood vessels that were obtained by means
of laser microdissection from human ischemic brains. Using multiple ELISA Searchlight 
®
array we evaluated
nine chemokines (CCL1 −5, CCL11, CCL17, CCL22, and CXCL8) in microdissected samples. We found higher
levels of CCL1 and CCL2 in neurons than in vessels; CCL5 and CCL22 were decreased in the infarcted areas. 
The same ELISA array was performed in plasma samples from stroke patients. We explored the temporal
proﬁle of circulating chemokines from admission to 90 days after the cerebrovascular event, and found that
only CCL22 showed signiﬁcant changes along time and that these changes negatively correlated with neuro-
logical severity. When neurological outcome was assessed in the hyperacute phase of stroke no associations
were found. 
From our study, we can conclude that these chemokines do not perform a clear role of outcome biomarkers.
Further studies are necessary to assess which mechanisms underlie the association of chemokines with the
neurological state at distinct time points since the differences found here could be reﬂecting the dual role of
chemokines in neuroinﬂammation. 
c © 2014 Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Cell death after cerebral ischemia activates a series of molecular
mechanisms that promote the production of inﬂammatory media-
tors, such as cytokines and chemokines, involved in leukocytes re-
cruitment to the injured tissue [ 1 ]. Once reached the site of ischemic
insult, leukocytes amplify the signal of cytokines contributing to tis-
sue damage and growth of the infarct core. As a result, this process
triggers brain inﬂammation and increases stroke severity [ 2 ]. On the
other hand, the physiological functions of leukocytes are phagocyto-
sis and clearance of dying cells and debris. In that context, a dual role* Corresponding author at: Neurovascular Research Laboratory, Vall d ’ Hebron Insti- 
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http://dx.doi.org/10.1016/j.trprot.2014.03.001 has been hypothesized, with neuroinﬂammation being both delete-
rious and restorative and thus, making this pathway an interesting
target to be therapeutically modulated [ 3 ]. 
In that scenario, chemokines act mainly via recruiting effector
leukocytes to the ischemic brain. CC and CXC chemokines seem the
most relevant subfamilies in cerebral ischemia, since they recruit
neutrophils and monocytes, which present an important phagocytic
activity [ 4 ]. A wide number of studies focused on the analysis of
chemokines evidence their relevant role in cerebral ischemia and
show an increased expression of these molecules within the ischemic
brain regions. However, non-concluding remarks can be obtained re-
garding its plausible role as biomarkers in the diagnosis or prognosis
of stroke ( Table 1 ). 
The response to inﬂammation within the brain involves all the cel-
lular components of the neurovascular unit as both, producers of and
responders to inﬂammatory molecules. As examples, endothelial cells
express cell adhesion molecules that facilitate leukocytes inﬁltration
in response to chemokines; glial cells can secrete chemokines after
ischemic stimulus; and neurons suffer the deleterious effects of in-
ﬂammation in the injured tissue (reviewed in [ 5 ]). On the other hand,
chemokines are also involved in other biological functions affectingle under the CC BY-NC-ND license ( http: // creativecommons.org / licenses / by-nc-nd / 
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Table 1 
CC and CXC chemokines in cerebral ischemia. 
Chemokine Ischemic stroke patients Animal models of stroke In vitro models of stroke NVU producing cell 
CCL1 Not known Not known Not known Not known 
CCL2 Increased in acute human CSF 
[ 25 ], whereas controversial 
results were found in blood with 
respect to controls [ 26 –29 ]. 
Stable circulating levels after 
stroke [ 28 ], with higher blood 
levels in those patients with 
poor long-term outcome [ 28 , 30 ] 
and recurrence [ 31 ]. However, 
higher levels 3 days after stroke 
were associated with 
neurological improvement [ 32 ]. 
Higher concentration in 
infarcted hemisphere [ 33 , 34 ]. 
KO animal showed decreased 
infarct volume [ 35 , 36 ] and 
reduction of BBB leakage [ 37 ], 
while CCL2 overexpression 
increased infarct volume and 
leukocytes inﬁltration [ 38 ]. On 
the other hand, CCL2 attract 
neuroblasts to infarcted zone 
[ 39 , 40 ]. CCL2 expression has a 
role in ischemic tolerance [ 41 ]. 
Increased expression in 
microvessel endothelial culture 
after 24 h OGD [ 42 ] and after 
reperfusion in BBB [ 43 ]. 
Neuron (ﬁrst [ 41 , 44 ]), astrocyte, 
endothelial cell. Increased CCL2 
expression in LMD-active vessels in 
human brain after stroke [ 42 ]. 
CCL3 Higher serum levels 1–3 days 
after stroke [ 28 ], although no 
differences where found when 
compared to asymptomatic 
carotid stenosis [ 45 ]. Regarding 
outcome, there is not a 
concluding association [ 28 , 32 ]. 
Higher concentration in 
infarcted hemisphere [ 34 ], being 
maintained 14 days after 
ischemia [ 46 ]. Exogenous CCL3 
increased infarct volume [ 47 ]. 
Not known Neuron, astrocyte, microglia 
(constitutive). 
CCL4 No differences in serum levels 
when compared to 
asymptomatic carotid stenosis 
[ 45 ]. 
Higher expression in ischemic 
brain [ 48 , 49 ]. 
OGD-injured microvascular 
endothelial culture secretes 
CCL4 [ 50 ]. 
Not known 
CCL5 Stable circulating levels after 
stroke [ 28 ]. No differences in 
concentration when compared 
to controls [ 28 ], but higher 
levels when compared with 
patients with asymptomatic 
carotid stenosis [ 45 ]. 
KO animals showed smaller 
infarcts [ 51 ]. In immature rats 
there is a limited induction of 
CCL5 1–14 days after ischemia 
[ 48 ]. 
Not known Not known 
CCL7 Not known Higher expression in ischemic 
hemisphere [ 52 ]. 
Not known Not known 
CCL9 Not known Higher expression in ischemic 
cortex [ 53 ]. 
Not known Not known 
CCL11 Not known No expressed in brain after 
ischemia [ 48 ]. 
Not known Not known 
CCL17 Not known Not known Not known Not known 
CCL20 Not known Increased levels after brain 
ischemia-reperfusion [ 54 ]. Use 
of a neutralizing antibody 
markedly reduced infarct 
volume [ 55 ]. 
Not known Astrocyte. 
CCL21 Not known Increased expression in 
ischemic brains [ 56 ]. 
Not known Neuron. 
CCL22 Not known Not known Not known Not known 
CXCL1 Higher CSF levels [ 57 ], but not 
concluding association in serum 
[ 57 , 58 ]. 
Increased expression in 
infarcted brain [ 49 , 59 , 60 ]. There 
is controversy regarding 
circulating levels [ 59 , 60 ]. 
Not known Astrocyte, microglia. 
CXCL2 Not known Increased expression in the 
infarcted hemisphere [ 60 ]. 
Not known Not known 
CXCL4 Increased in plasma from stroke 
patients and higher levels 
associated with disability [ 61 ]. 
CXCL4 levels diminished along 
time [ 62 ]. 
Not known Not known Not known 
CXCL5 Higher levels in CSF but not in 
serum [ 63 ]. 
Not known Not known Not known 
CXCL8 Higher circulating levels than in 
controls [ 58 ], being maintained 
for a week [ 64 ]. 
CXCL8 inhibition reduced infarct 
size and neurological deﬁcit 
[ 65 ]. 
Not known Not known 
CXCL10 Higher levels in ischemic brain 
[ 66 ]. 
Increased expression in 
infarcted brain [ 49 , 67 ], which is 
maintained along time [ 68 ]. 
Not known Neuron (ﬁrst), glia. 
CXCL11 Not known Increased expression in 
infarcted brain [ 49 ]. 
Not known Not known 
CXCL12 Plasma levels slightly increased 
with time after stroke onset [ 69 ] 
and peak 24 h later [ 70 ], 
although there are not clear 
differences with controls 
[ 69 , 71 ]. Controversial results 
regarding correlation with 
initial severity [ 69 , 72 ]. 
Expression increases in infarct 
core and penumbra [ 49 , 73 ]. 
Over-expression of CXCL12 after 
ischemia induced a delayed 
neuroprotection [ 74 ]. 
Not known Endothelial cell, astrocyte, microglia, 
neuron. 
CXCL13 Not known Increased expression in 
infarcted brain [ 49 ]. 
Not known Not known 
CXCL16 Higher circulating levels when 
compared to controls [ 75 ]. 
Higher plasma levels in the 
subacute phase of stroke 
patients who will die due to 
cardiovascular disease [ 76 ]. 
Not known Not known Endothelial cell, microglia, astrocyte. 
Chemokines in bold are chemokines included in SearchLight 
®
Human chemokine Array; for the rest of known CC and CXC chemokines that are not in the list, we did not ﬁnd any publication 
in cerebral ischemia. 
BBB: blood brain barrier; CSF: cerebrospinal ﬂuid; KO: knock-out; LMD: laser microdissection; NVU: neurovascular unit; OGD: oxygen and glucose deprivation. 
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 neurovascular unit components, such as angiogenesis or neuronal
survival [ 6 ]. 
Considering all these precedents, we aimed to study the expres-
sion of chemokines by several components of the neurovascular unit
after stroke. For that purpose, we have combined two precise tech-
niques: a multiple ELISA array of nine chemokines from CC and CXC
families and laser microdissection to obtain neurons and blood brain
vessels from patients who died following an ischemic stroke. More-
over, in order to assess the plausible use of chemokines as biomarkers
or therapeutic targets in stroke ﬁeld, we evaluated their temporal pro-
ﬁle in blood samples and their association with stroke severity and
outcome. 
2. Materials and methods 
2.1. Brain tissue samples 
Four deceased patients who had an ischemic stroke secondary
to middle cerebral artery (MCA) occlusion within the previous 4 days
(range, 40–100 h) were included in this part of the study (Supplemen-
tary Table 1). Brain tissue sampling from infarcted core and healthy
contralateral areas was performed within the ﬁrst hours after death
according to our previously published procedure [ 7 ]. All samples were
snap frozen in liquid nitrogen and immediately stored at −80 ◦C until
use. 
2.2. Clinical protocol and blood samples 
Differential diagnosis of stroke was based on clinical examination
by an expert neurologist and supported by computed tomography. In
all cases, stroke onset was deﬁned as the last time the patient was
known to be asymptomatic. Description of demographic and clini-
cal factors of patients that were included in this study is shown in
Supplementary Table 2. 
Patients from the placebo arm of the MISTICS study [ 8 ] were con-
sidered for exploring blood temporal proﬁle. From that cohort, 20
patients with a cortical ischemic stroke admitted to the emergency
department within the ﬁrst 3–12 h after symptoms onset were in-
cluded in the study. No patient was known to have any inﬂamma-
tory (infectious and immunologic) or malignant disease and none
of them received thrombolytic treatment. Peripheral blood samples
were drawn from each patient at admission, day 1, 3, 7 and 90. Com-
plete temporal proﬁle was achieved for 15 patients. 
On the other hand, we wanted to analyze the presence of
chemokines in the hyperacute phase ( < 4.5 h) of stroke and their
relationship with outcome. For that purpose, we included 36 is-
chemic stroke patients admitted within the ﬁrst 4.5 h after onset.
None of these patients was known to have inﬂammatory or malignant
diseases. Blood samples were obtained before all of them received
thrombolytic treatment [standard dose of 0.9 mg / kg recombinant
tissue-plasminogen activator (rt-PA)]. Consecutive patients were se-
lected from this cohort to balance the sample size in all outcome
groups (improvement, stability or worsening of the neurological state
during in-hospital stay). 
Neurological severity was assessed by using the National Institutes
of Health Stroke Scale (NIHSS) [ 9 ]. All included patients had a NIHSS
score from 2 to 23, ranging from mild to severe neurological impair-
ment. We deﬁned neurological improvement as a decrease in NIHSS
score by ≥4 points during in-hospital stay [ 10 ]. Clinical and neu-
roimaging data obtaining was blinded to the results of chemokines
array. 
In all cases, plasma was immediately separated by centrifugation
at 1500 × g for 15 min at 4 ◦C and stored at −80 ◦C until use. 
The local ethical committee approved both studies (i.e., human
brain tissue and blood sampling), and written consent was obtainedfrom all patients or relatives in accordance with the Helsinki declara-
tion. 
2.3. Immuno-laser microdissection 
Frozen brain samples were embedded in Tissue-Tek OCT (Sakura
Finetek, Europe, The Netherlands) and 10 μm-thick sections were
cut using a cryostat (Leica CM3050 S; Leica Microsystems, Germany).
Sections were mounted on 2 μm PEN-membrane slides (MicroDis-
sect GmbH, Germany) and stored at −80 ◦C. Neurons were stained
using a mouse anti-NeuN antibody (1:50; Chemicon, USA) and brain
microvessels were stained using Ulex europeaus Agglutinin I (UEA I)
lectin (1:20; Sigma–Aldrich, USA) following the procedure as previ-
ously described [ 11 ]. 
Laser microdissection (LMD) was performed on an LMD6000 mi-
croscope (Leica). Cells were dissected into dry 0.2 mL tube caps at
a power of 41–45 kW and a speed of 14 ns using a 20 × objective.
Total areas of approximately 2,000,000 μm 2 of each cell type (5000–
7000 cells) were pooled from several dissections from both infarct
and contralateral brain tissue. Cells were recovered in 140 μL of cold
lysis buffer (50 mM Tris–HCl, pH 7.6, 150 mM NaCl, 5 mM CaCl 2 ,
0.05% Brij-35, 0.02% NaN 3 and 1% Triton X-100) containing protease
inhibitors (1 mM PMSF and 7 μg / mL aprotinin), vortexed for 5 min,
centrifuged at 12,000 × g for 10 min at 4 ◦C and stored at −80 ◦C
until use. Total protein content of the samples was determined by
bicinchoninic acid assay (microBCA, Pierce, USA), yielding on average
83.6 μg / mL. 
2.4. Multiplexed SearchLight 
®
chemokines protein array 
A multiplexed sandwich ELISA (SearchLight 
®
Human Chemokine
Array, Aushon Biosystems, USA) was used with LMD-cells and plasma
samples for the simultaneous quantitative measurement of nine
chemokines: CC or β-chemokines (I-309 / CCL1, MCP-1 / CCL2, MIP-
1 α/ CCL3, MIP-1 β/ CCL4, RANTES / CCL5, Eotaxin / CCL11, TARC / CCL17
and MDC / CCL22) and CXC or α-chemokines (IL-8 / CXCL8). The chemi-
luminescent signal detected with a cooled CCD camera (Pierce, USA)
was analyzed with ArrayVision 8.0 software (Imaging Research, USA).
The sensitivity limit for each molecule was: CCL1 (0.8 pg / mL), CCL2
(0.8 pg / mL), CCL3 (3.1 pg / mL), CCL4 (0.8 pg / mL), CCL5 (0.4 pg / mL),
CCL11 (0.5 pg / mL), CCL17 (0.4 pg / mL), CCL22 (0.2 pg / mL) and CXCL8
(0.2 pg / mL) as provided by the manufacturer. For LMD-samples, all
values below the limit of detection were assigned with the corre-
sponding limit value. 
We strictly followed the manufacturer ’ s instructions and con-
ducted the assay in a blinded manner. LMD and plasma samples
(with exception of temporal proﬁles) were assayed twice and the
mean value of both measurements was given. For LMD-cell samples
the resulting chemokine protein concentration was ﬁnally corrected
by the total protein content and values are given as pg / mg. Plasma
results were expressed as pg / mL. 
2.5. Statistical analyses 
Whole analysis was performed with SPSS 15.0 software (SPSS Inc.,
USA). 
Shapiro–Wilk test was used to deﬁne normally distributed vari-
ables ( p > 0.05), due to small sample sizes. Normal distribution was
analyzed by Students ’ t test or ANOVA and mean and SD values were
given. Different time points of temporal proﬁles were compared by
ANOVA of repeated measures and paired- t test, while correlations
with other continuous variables were assessed by Pearson test. 
Non-normal distribution was assessed by Mann–Whitney U or
Kruskal–Wallis tests and median and interquartile range (IQR) were
reported. We compared temporal proﬁles by Friedman and Wilcoxon
tests, and analyzed correlations by Spearman test. 
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In all cases, a p -value < 0.05 was considered statistically signiﬁcant 
t a 95% conﬁdence level. 
For sample size and statistical power calculation we compared 
edians by using Ene 3.0 free software (GlaxoSmithKline S.A., Spain; 
ttp: // sct.uab.cat / estadistica / es ). 
. Results 
.1. Chemokines in human brain after stroke 
Of the nine chemokines assayed, CCL3, CCL4 and CCL17 were not 
etected in LMD-cell samples. Among the remaining six chemokines, 
CL1 and CCL2 were found at higher levels in neurons than in blood 
essels ( p = 0.021 in both cases) only in healthy contralateral area. 
nterestingly, CCL5 and CCL22 were decreased within the vessels and 
eurons, respectively, when the contralateral region of the brain was 
ompared to the infarcted tissue (both cases with a p = 0.043) ( Fig. 
 ). 
.2. Blood detection of chemokines after stroke 
All the nine chemokines were detected in plasma samples of is- 
hemic stroke patients and, as shown in Supplementary Table 2, no 
ifferences regarding demographic and clinical data were found be- 
ween both studied cohorts. 
We explored the temporal proﬁle of the plasma levels of these 
hemokines in a non-rt-PA treated cohort in order to avoid a possible 
nﬂuence of the thrombolytic treatment in the concentration of these 
olecules. Most chemokines showed stable circulating levels over 
ime. As an exception, CCL22 concentration presented a signiﬁcant 
ecrease during the acute phase ( p = 0.004) and reached a peak 7 days 
fter the event ( p = 0.01) ( Fig. 2 ). This reduction on CCL22 levels 
ithin the ﬁrst three days after stroke was negatively correlated with 
troke severity at different time points: the lower the CCL22 levels, 
he higher the NIHSS score. Weaker negative correlations with stroke 
everity were found for CCL17 levels one day after stroke although no 
igniﬁcant change in blood levels was seen throughout time ( Table 
 ). 
.3. Chemokines and stroke outcome 
In view of these associations with neurological severity, we stud- 
ed the plausible role of these chemokines as early outcome biomark- 
rs in the hyperacute phase of stroke. No differences in chemokine 
evels at admission were found when the two studied cohorts were 
ompared, with exception of CCL4, CCL5 and CXCL8. In these cases, 
he differences may be due to technical variability among lots (data 
ot shown). 
Only CCL3 showed a trend to be higher in those patients who im- 
roved within 24 h ( p = 0.098) ( Table 3 ). None of the chemokines that 
howed a negative correlation with stroke severity were found to be 
ssociated with early outcome in rt-PA treated patients. Calculations 
f the sample size needed revealed that a large number of patients in 
ach outcome group would be necessary to achieve statistical signif- 
cant association at an 80% of power ( Table 3 ). 
. Discussion 
Extensive research regarding the role of chemokines in both phys- 
ological and pathological states of the central nervous system has 
een published and reviewed. Although some chemokines are con- 
titutively expressed at low level in the brain in order to maintain 
omeostasis (like Fractalkine / CX3CL1 in neurons or CXCL12 in astro- 
ytes), their expression is induced after brain injury mainly in resident cells, activated local cells and inﬁltrated leukocytes. The induction of 
the expression of chemokines is mediated by cytokines such as tumor 
necropsy factor alpha (TNF- α), interleukin 1 (IL-1) and IL-6 that act 
as inﬂammatory mediators as part of the ischemic cascade [ 12 ]. Thus 
chemokines contribute to an inﬂammatory state that could be either 
detrimental or beneﬁcial [ 13 ]. The most remarkable chemokines that 
have been described in pathological states include CCL2 to CCL5 and 
CXCL8 [ 14 ]. 
In the context of cerebral ischemia, it has been hypothesized that 
the inter-relationship between different components of the neurovas- 
cular unit contributes to the post-ischemic inﬂammatory state [ 5 ]. 
However, to the best of our knowledge, the study of inﬂammation in 
ischemic brains has been focused mainly on the individual compo- 
nents of the neurovascular unit using, for example, cell cultures of 
immortalized human cell lines of neurons or endothelial cells. These 
are considered a reduced context since only one single, or very few 
cell types, are represented. In other less simple approaches, some in 
vivo models, usually performed in rodents, have been used as well, 
although the immune system response manifest some differences 
when compared to humans [ 15 , 16 ]. 
Here, we present our results of the levels of chemokines in indi- 
vidual neurons and brain vessels but isolated by LMD from a global 
context as can be human brains that suffered an ischemic event. More- 
over, the method presented here couples contact-free LMD to the 
immunoﬂuorescence detection of the cells of interest in fresh-frozen 
tissues, thus granting the obtaining of pure populations of individ- 
ual cells and good-quality proteins for further analyses. In this way, 
instead of a simple qualitative histological comparison, LMD allows 
a semi-quantitative measurement of the amount of chemokines in 
microvessels and neurons isolated from different brain areas. 
Astrocytes and other glial cells are important parts of the neu- 
rovascular unit. These cells act as connectors between vessels and 
neurons, and are main characters in neuroinﬂammation. As sum- 
marized in Table 1 , astrocytes and other glial cells express some 
chemokines of the CXC and CC families. For instance, so far CCL20 
seems to be exclusively expressed by astrocytes and important in the 
recruitment of speciﬁc leukocytes to the central nervous system to 
regulate the immune response [ 17 ]. However, we did not microdis- 
sect these cell types mainly because of their complex shape, pro- 
longations and processes that complicate their pure isolation from 
the whole parenchyma of human brain samples. As a consequence 
of this characteristic morphology, the measurement of chemokines ’ 
expression might be biased. 
The use of an antibodies array combining different chemokines 
has allowed us to assess the levels of nine of these proteins in brain 
and in blood at the same time and in the same cohort of patients. This 
array included some ccs chemokines that, at least to our knowledge, 
have never been studied in cerebral ischemia, such as CCL1, CCL17 or 
CCL22, together with more studied chemokines as CCL2. 
CCL22 concentration was reduced in the infarct core of damaged 
tissue after cerebral ischemia and also in systemic circulation 24 h 
after stroke symptoms onset. Moreover, lower circulating levels were 
associated with sustained stroke severity. Altogether, these results 
suggest that a decrease in the expression of CCL22 is related to poor 
outcome in stroke patients. On the other hand, CCL17 was not de- 
tected in LMD-cells but it showed a similar association regarding to 
low circulating levels and stroke severity. Interestingly, CCL17 and 
CCL22 co-localize in the same chromosomal loci, are similar in their 
sequence and share CCR4 as a receptor [ 18 ]. CCR4 is expressed in Th2 
leukocytes, thus being CCL17 and CCL22 ampliﬁers of the immune 
response of type II [ 19 ]. A systemic shift of the immune system to- 
wards anti-inﬂammatory type II response has been described in the 
post-acute phase of cerebral ischemia [ 20 ]. This anti-inﬂammatory 
state leads to immunodepression that could be considered a pro- 
tective adaptative reaction to suppress the aggressive Th1 response 
against presented endogenous brain antigens. Therefore, in spite of 
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Table 2 
Correlations between blood levels of chemokines and severity of stroke. 
Chemokine NIHSS Adm. NIHSS 1d NIHSS 3d NIHSS 5d NIHSS 7d 
CCL1 Adm. R = –0.168; p = 0.478 R = –0.020; p = 0.932 R = –0.092; p = 0.701 R = 0.065; p = 0.790 R = 0.041; p = 0.867 
CCL1 1d R = –0.116; p = 0.635 R = –0.108; p = 0.660 R = –0.165; p = 0.500 R = –0.301; p = 0.224 R = –0.276; p = 0.268 
CCL1 3d R = 0.359; p = 0.132 R = 0.143; p = 0.560 R = 0.293; p = 0.224 R = 0.103; p = 0.685 R = 0.146; p = 0.563 
CCL1 7d R = –0.224; p = 0.357 R = –0.057; p = 0.815 R = –0.079; p = 0.747 R = –0.103; p = 0.676 R = –0.083; p = 0.736 
CCL2 Adm. R = –0.271; p = 0.248 R = –0.434; p = 0.056 * R = –0.339; p = 0.143 R = –0.500; p = 0.029 R = –0.450; p = 0.053 * 
CCL2 1d R = –0.260; p = 0.282 R = –0.193; p = 0.429 R = –0.399; p = 0.091 * R = –0.369; p = 0.132 R = –0.297; p = 0.232 
CCL2 3d R = –0.222; p = 0.360 R = –0.184; p = 0.451 R = –0.438; p = 0.061 * R = –0.402; p = 0.098 * R = –0.343; p = 0.163 
CCL2 7d R = –0.104; p = 0.671 R = –0.174: p = 0.476 R = –0.206; p = 0.397 R = –0.214; p = 0.380 R = –0.215; p = 0.377 
CCL3 Adm. R = 0.056; p = 0.815 R = –0.106; p = 0.656 R = 0.077; p = 0.747 R = –0.064; p = 0.795 R = –0.042; p = 0.863 
CCL3 1d R = –0.001; p = 0.997 R = –0.227; p = 0.350 R = –0.194; p = 0.426 R = –0.355; p = 0.148 R = –0.325; p = 0.188 
CCL3 3d R = –0.034; p = 0.890 R = 0.003; p = 0.990 R = 0.181; p = 0.457 R = 0.131; p = 0.604 R = 0.188; p = 0.455 
CCL3 7d R = –0.012; p = 0.960 R = –0.039; p = 0.874 R = –0.133; p = 0.586 R = –0.205; p = 0.400 R = –0.231; p = 0.341 
CCL4 Adm. R = 0.012; p = 0.959 R = –0.108; p = 0.649 R = –0.007; p = 0.977 R = –0.075; p = 0.762 R = –0.055; p = 0.823 
CCL4 1d R = 0.108; p = 0.660 R = –0.067; p = 0.785 R = –0.020; p = 0.934 R = –0.023; p = 0.928 R = –0.025; p = 0.921 
CCL4 3d R = –0.099; p = 0.687 R = –0.135; p = 0.581 R = 0.135; p = 0.581 R = 0.276; p = 0.268 R = 0.297; p = 0.232 
CCL4 7d R = –0.087; p = 0.723 R = –0.252; p = 0.298 R = –0.114; p = 0.642 R = –0.145; p = 0.553 R = –0.195; p = 0.425 
CCL5 Adm. R = 0.239; p = 0.310 R = 0.138; p = 0.561 R = 0.201; p = 0.396 R = 0.006; p = 0.981 R = 0.014; p = 0.955 
CCL5 1d R = 0.321; p = 0.180 R = 0.070; p = 0.776 R = 0.244; p = 0.314 R = 0.112; p = 0.657 R = 0.165; p = 0.512 
CCL5 3d R = 0.584; p = 0.009 R = 0.423; p = 0.071 * R = 0.334; p = 0.163 R = 0.188; p = 0.456 R = 0.183; p = 0.467 
CCL5 7d R = 0.356; p = 0.135 R = 0.385; p = 0.104 R = 0.281; p = 0.244 R = 0.183; p = 0.454 R = 0.188; p = 0.441 
CCL11 Adm. R = 0.083; p = 0.726 R = –0.118; p = 0.620 R = –0.130; p = 0.585 R = –0.095; p = 0.699 R = –0.043; p = 0.862 
CCL11 1d R = 0.262; p = 0.279 R = 0.255; p = 0.293 R = 0.084; p = 0.732 R = 0.316; p = 0.202 R = 0.308; p = 0.214 
CCL11 3d R = 0.147; p = 0.548 R = 0.012; p = 0.961 R = 0.002; p = 0.994 R = 0.021; p = 0.935 R = –0.014; p = 0.955 
CCL11 7d R = –0.035; p = 0.886 R = –0.095; p = 0.700 R = –0.110; p = 0.654 R = –0.147; p = 0.549 R = –0.153; p = 0.532 
CCL17 Adm. R = –0.286; p = 0.221 R = –0.451; p = 0.046 R = –0.311; p = 0.183 R = –0.281; p = 0.244 R = –0.266; p = 0.272 
CCL17 1d R = –0.441; p = 0.059 * R = –0.510; p = 0.026 R = –0.534; p = 0.019 R = –0.476; p = 0.046 R = –0.466; p = 0.051 * 
CCL17 3d R = 0.273; p = 0.259 R = 0.075; p = 0.761 R = 0.080; p = 0.744 R = –0.046; p = 0.856 R = –0.057; p = 0.822 
CCL17 7d R = 0.287; p = 0.234 R = 0.262; p = 0.279 R = 0.283; p = 0.241 R = 0.260; p = 0.282 R = 0.242; p = 0.318 
CCL22 Adm. R = –0.074; p = 0.755 R = –0.208; p = 0.380 R = –0.054; p = 0.820 R = –0.075; p = 0.761 R = –0.077; p = 0.753 
CCL22 1d R = –0.335; p = 0.161 R = –0.576; p = 0.010 R = –0.562; p = 0.012 R = –0.522; p = 0.026 R = –0.532; p = 0.023 
CCL22 3d R = –0.486; p = 0.035 R = –0.676; p = 0.001 R = –0.694; p = 0.001 R = –0.587; p = 0.010 R = –0.561; p = 0.015 
CCL22 7d R = –0.142; p = 0.561 R = –0.192; p = 0.432 R = –0.065; p = 0.791 R = –0.070; p = 0.775 R = –0.128; p = 0.603 
CXCL8 Adm. R = 0.115; p = 0.631 R = 0.022; p = 0.927 R = 0.216; p = 0.361 R = 0.057; p = 0.818 R = 0.114; p = 0.642 
CXCL8 1d R = 0.060; p = 0.808 R = –0.062; p = 0.802 R = –0.133; p = 0.588 R = –0.139; p = 0.582 R = –0.123; p = 0.626 
CXCL8 3d R = –0.164; p = 0.502 R = –0.123; p = 0.615 R = –0.036; p = 0.883 R = 0.009; p = 0.971 R = 0.017; p = 0.945 
CXCL8 7d R = 0.555; p = 0.014 R = 0.292; p = 0.226 R = 0.439; p = 0.060 * R = 0.257; p = 0.288 R = 0.249; p = 0.303 
Correlation coefﬁcients ( R ) and p -values are given for each comparison. Signiﬁcant correlations were in bold. 
Adm.: at admission; NIHSS: National Institutes of Health Stroke Scale. 
∗Stands for statistical trend ( p < 0.1). 
Table 3 
Plasma levels of chemokines and neurological improvement in the acute phase of stroke. 
Chemokine Neurological improvement at 24 h Statistical power 
No ( N = 24) Yes ( N = 12) p -Value Power Sample size for each group 
CCL1 67.8 (57.5–80.1) 87.2 (64.5–100.7) 0.409 13.2% 188 
CCL2 443.7 (361.9–605.2) 486.1 (416.6–604.4) 0.514 9.7% 306 
CCL3 135.6 (96.6–155.4) 185.5 (137.6–282.1) 0.098 * 39.1% 50 
CCL4 244.2 (184.5–276.9) 191.7 (177.3–328.7) 0.619 7.2% 719 
CCL5 NA NA − − −
CCL11 191.6 (165.5–240.3) 176.1 (151.0–201.3) 0.271 19.9% 153 
CCL17 98.7 (56.1–120.9) 88.1 (82.3–118.1) 0.963 2.8% 75,835 
CCL22 433.0 (396.2–620.0) 531.7 (475.4–612.4) 0.367 14.8% 215 
CXCL8 2.0 (2.0–4.5) 6.2 (2.0–19.2) 0.464 10.5% 328 
Neurological improvement considered as a decrease of 4 or more points in NIHSS score from admission to 24 h (identical results were obtained for improvement at 48 h; data not 
shown). All chemokine values are given as pg / mL. 
Statistical power calculations based on the results obtained for improvement at 24 h; `sample size for each group” indicates the number of patients needed in the groups of 
improvement and no-improvement to reach statistical signiﬁcance at an 80% of power. 
CCL5 values were over the corresponding curve in this plate (non-available (NA) results). 
NIHSS: National Institutes of Health Stroke Scale. 
∗Stands for statistical trend ( p < 0.1). 
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Fig. 1. Chemokines levels in human brain microdissected-samples. Results of six chemokines are given in pg / mg of total protein for both neurons and blood vessels. Box-plots 
represent median and interquartile range. White boxes correspond to contralateral area (CL) and gray boxes correspond to infarcted area (IC). * p < 0.05. 
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seing beneﬁcial, the enhanced Th2 response might increase the risk 
f detrimental secondary infections [ 21 , 22 ]. In that context, the mod- 
lation of the immune system by the use of monoclonal antibodies 
ould be of interest in stroke as well as in other diseases with an 
nﬂammatory background [reviewed in 23 ]. 
Our results showed a very faint power for CCL17 and CCL22 to 
iscriminate those patients who will improve within the ﬁrst 24–
8 h after stroke. Thus, none of these chemokines seem a reliable 
rognostic biomarker in the hyperacute phase of stroke, when quick 
ecision-making is needed to start a more exhaustive management 
n order to avoid secondary complications. 
However, the results of our study might inspire new lines of inves- 
igation focused on the modulation of CCL17 and / or CCL22 or even 
CR4. 
Our study stands with some limitations. We cannot dismiss the 
ossible presence of some astrocyte end-feet in our vessel samples, 
ince in brain tissue these cell types are tightly interrelated to form the 
lood–brain-barrier. We cannot dismiss out of hand the fact that the 
oncentration of chemokines in systemic circulation could contribute 
o their quantiﬁcation in LMD-vessels since necropsies might contain 
races of blood in vessel lumens. Nevertheless, the undetectable con- 
entration of some of these chemokines in LMD-vessels may suggest 
 minimal contribution of the circulating levels of each chemokine to 
ts amount in the LMD samples. On the other hand, human brain sam- 
les from stroke patients are scarce and thus the small sample size 
sed in this part of the study might affect the results on chemokine 
evels. 
Regarding blood samples, we were not able to study the relation 
etween chemokines and neurological outcome in the MISTIC cohort 
ue to the limited number of worsening / improvement cases. More- 
ver, the sample size used for the study in the hyperacute phase is 
elatively small, but the sample size calculations showed a very large 
umber of samples needed to get signiﬁcant results for most of the 
tudied chemokines. Further studies are necessary to answer if CCL17 or CCL22 could have a role as outcome biomarkers at a later point 
in time after hyperacute phase. Other chemokines not included in 
SearchLight 
®
array might be of interest in stroke ﬁeld, especially 
some of them that have not been studied in human stroke (CCL7, 
CCL9, CXCL2). Novel multiplexed immunoassays based on ﬂuores- 
cently encoded microspheres might increase the screening of circu- 
lating inﬂammatory molecules in stroke patients while using very 
few amount of sample [ 24 ]. 
5. Conclusions 
In conclusion, we quantiﬁed some chemokines in neurons and 
brain blood vessels and described how these chemokines behave in 
plasma following ischemic stroke. The results reported suggest a dif- 
ferent role for these chemokines along time with regards to neuro- 
logical state. On the other hand, the studied chemokines does not 
seem of interest as outcome biomarkers, at least in the hyperacute 
phase. Further investigation is needed to assess if chemokines could 
be therapeutic targets to modulate neuroinﬂammation after ischemic 
stroke. 
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Fig. 2. Chemokines temporal proﬁles in plasma samples from ischemic stroke patients. Results are given in pg / mL, from admission (Adm.) to day 90 after the event. Box-plots 
represent median and interquartile range, with overlapping dot-plot to show the distribution of the values. * p < 0.05 and ** p ≤ 0.01. 
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